Latest Conference Articles

The efficacy results demonstrated that there were 4 patients with confirmed partial response, and an additional 3 patients had stable disease lasting 16 weeks or longer.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic the next steps for his CAEL-101 findings, a treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about what CAEL-101 is, how it works, and how it is used to treat patients with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.

Data from a phase 1b/2 trial investigating the treatment of CCA with the combination of silmitasertib plus gemcitabine and cisplatin in comparison with gemcitabine and cisplatin found a statistically significant difference.

The treatment of 5-fluorouracil with levofolinate and irinotecan was found to be well-tolerated and effective as a second-line treatment for patients with gemcitabine-refractory advanced pancreatic cancer.

Data from a phase 1b/2 study investigating onvansertib as a treatment of KRAS-mutated mCRC demonstrated that 42% of patients achieved a PR and 67% demonstrated a durable response ranging from 6.1 months to 13.7 months.

According to Senhwa Biosciences, the study’s findings indicate a clinically meaningful improvement in progression-free survival (PFS) (P

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the treatment considerations necessary to properly manage a patient with congenital plasminogen deficiency after she became pregnant.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the details of a patient who had a successful pregnancy despite documented infertility due to congenital plasminogen deficiency.

The objective of the study was to evaluate the impact of the ambulatory care pharmacist intervention on A1C changes in patients with uncontrolled type 2 diabetes mellitus (T2DM) during a 2-year period at the diabetes education center.

Pharmacists play a key role in educating patients on risk factors for cervical and endometrial cancers and can assist with treatment decisions, and management of potential adverse effects in patients with these cancers.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the disease impact on the gynecologic system and how often patients become infertile due to this impact.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, details the treatment options available for patients with congenital plasminogen deficiency.

Telehealth has been crucial in expanding access to naloxone, a lifesaving drug used to reverse the effects of an opioid overdose.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, describes common manifestations of congenital plasminogen deficiency and their impact on patient outcomes.

Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses why congenital plasminogen deficiency is often underdiagnosed and describes the causes and characteristics of the disorder.

Updated phase 3 progression-free survival and overall survival data demonstrated clinical benefits in efficacy and tolerability of oral paclitaxel and encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.

Rami Komrokji, MD, discusses what the MOST study's results mean for investigating second-line treatment options in myelofibrosis.

CAR T-cell therapy associated with greater anti-cancer activity in treating multiple myeloma.

Under the 340B Prime Vendor Program, the Prime Vendor has several functions that it carries out to support stakeholders in operating and navigate the field so that they can effectively achieve lower 340B drug pricing for those who need it most.

Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.

Wearable technology and apps that monitor health and wellness have exploded in popularity and sophistication in recent years.

Rami Komrokji, MD, discusses common prior treatments of low-risk and intermediate-1 risk patients in the MOST study.

Delirium is a common syndrome experienced by patients with COVID-19 while being treated in the ICU, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

Monitoring outpatient prescribing patterns has been a major challenge for the Lifespan health system in Rhode Island, since it has over 1.5 million electronic prescriptions written annually.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.